Russo S, Incerti M, Tognolini M, Castelli R, Pala D, Hassan-Mohamed I, Giorgio C, De Franco F, Gioiello A, Vicini P, Barocelli E, Rivara S, Mor M, Lodola A. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor. Molecules. 2013 Oct 21;18(10):13043-60. doi: 10.3390/molecules181013043. PMID: 24152675
Ponzano S, Bertozzi F, Mengatto L, Dionisi M, Armirotti A, Romeo E, Berteotti A, Fiorelli C, Tarozzo G, Reggiani A, Duranti A, Tarzia G, Mor M, Cavalli A, Piomelli D, Bandiera T. Synthesis and structure-activity relationship (SAR) of 2-methyl-4-oxo-3-oxetanylcarbamic acid esters, a class of potent N-acylethanolamine acid amidase (NAAA) inhibitors. J Med Chem. 2013 Sep 12;56(17):6917-34. doi: 10.1021/jm400739u. Epub 2013 Aug 30. PMID: 23991897
Vacondio F, Carmi C, Galvani E, Bassi M, Silva C, Lodola A, Rivara S, Cavazzoni A, Alfieri RR, Petronini PG, Mor M. Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors. Bioorg Med Chem Lett. 2013 Oct 1;23(19):5290-4. doi: 10.1016/j.bmcl.2013.08.008. Epub 2013 Aug 11. PMID: 23988354
Moreno-Sanz G, Duranti A, Melzig L, Fiorelli C, Ruda GF, Colombano G, Mestichelli P, Sanchini S, Tontini A, Mor M, Bandiera T, Scarpelli R, Tarzia G, Piomelli D. Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors. J Med Chem. 2013 Jul 25;56(14):5917-30. doi: 10.1021/jm4007017. Epub 2013 Jul 3. PMID: 23822179
Rossi A, Buttini F, Colombo P, Mor M, Pala D, Bortolotti F, Colombo G. Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration. Int J Pharm. 2013 Jul 15;451(1-2):50-6. doi: 10.1016/j.ijpharm.2013.04.064. Epub 2013 Apr 27. PMID: 23628401
Chudyk EI, Dyguda-Kazimierowicz E, Langner KM, Sokalski WA, Lodola A, Mor M, Sirirak J, Mulholland AJ. Nonempirical energetic analysis of reactivity and covalent inhibition of fatty acid amide hydrolase. J Phys Chem B. 2013 Jun 6;117(22):6656-66. doi: 10.1021/jp401834v. Epub 2013 May 28. PubMed PMID: 23654226.
Pizzirani D, Pagliuca C, Realini N, Branduardi D, Bottegoni G, Mor M, Bertozzi F, Scarpelli R, Piomelli D, Bandiera T. Discovery of a new class of highly potent inhibitors of acid ceramidase: synthesis and structure-activity relationship (SAR). J Med Chem. 2013 May 9;56(9):3518-30. doi: 10.1021/jm301879g. PubMed PMID: 23614460.
Pala D, Beuming T, Sherman W, Lodola A, Rivara S, Mor M. Structure-based virtual screening of MT2 melatonin receptor: influence of template choice and structural refinement. J Chem Inf Model. 2013 Apr 22;53(4):821-35. doi: 10.1021/ci4000147. Epub 2013 Apr 9. PubMed PMID: 23541165.
Incerti M, Tognolini M, Russo S, Pala D, Giorgio C, Hassan-Mohamed I, Noberini R, Pasquale EB, Vicini P, Piersanti S, Rivara S, Barocelli E, Mor M, Lodola A. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. J Med Chem. 2013 Apr 11;56(7):2936-47. doi: 10.1021/jm301890k. Epub 2013 Mar 22. PubMed PMID: 23489211.
Lodola A, Capoferri L, Rivara S, Tarzia G, Piomelli D, Mulholland A, Mor M. Quantum mechanics/molecular mechanics modeling of fatty acid amide hydrolase reactivation distinguishes substrate from irreversible covalent inhibitors. J Med Chem. 2013 Mar 28;56(6):2500-12. doi: 10.1021/jm301867x. PMID: 23425199; PubMed Central PMCID: PMC3724458.
Sasso O, Moreno-Sanz G, Martucci C, Realini N, Dionisi M, Mengatto L, Duranti A, Tarozzo G, Tarzia G, Mor M, Bertorelli R, Reggiani A, Piomelli D. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models. Pain. 2013 Mar;154(3):350-60. doi: 10.1016/j.pain.2012.10.018. PubMed PMID: 23218523; PubMed Central PMCID: PMC3723234.
Rivara S, Piersanti G, Bartoccini F, Diamantini G, Pala D, Riccioni T, Stasi MA, Cabri W, Borsini F, Mor M, Tarzia G, Minetti P. Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors. J Med Chem. 2013 Feb 14;56(3):1247-61. doi: 10.1021/jm301686s. PubMed PMID: 23281824.
Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, Peters GJ, Petronini PG, Ardizzoni A. Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer. Curr Pharm Des. 2013;19(5):818-32. Review. PubMed PMID: 22973953.
Galvani E, Giovannetti E, Saccani F, Cavazzoni A, Leon LG, Dekker H, Alfieri R, Carmi C, Mor M, Ardizzoni A, Petronini PG, Peters GJ. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer. Neoplasia. 2013 Jan;15(1):61-72. PubMed PMID: 23359111; PubMed Central PMCID: PMC3556939.
Ochoa-Sanchez R, Rainer Q, Comai S, Spadoni G, Bedini A, Rivara S, Fraschini F, Mor M, Tarzia G, Gobbi G. Anxiolytic effects of the melatonin MT(2) receptor partial agonist UCM765: comparison with melatonin and diazepam. Prog Neuropsychopharmacol Biol Psychiatry. 2012 Dec 3;39(2):318-25. doi: 10.1016/j.pnpbp.2012.07.003. PubMed PMID: 22789661.